Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Affiliations

• ¹ Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
• ² National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel.
• ³ The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel.
• ⁴ Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy.
• ⁵ Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA.
• ⁶ Bayer AG, Berlin, Germany.
• ⁷ Bayer, Whippany, NJ, USA.
• ⁸ Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
• ⁹ The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
• ¹⁰ University Medical Center Groningen, Groningen, The Netherlands.
• ¹¹ Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA.
• ¹² Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. mariaelisa_mancuso@libero.it.
• ¹³ Humanitas University, Pieve Emanuele, Milan, Italy. mariaelisa_mancuso@libero.it.